Skip to main content
Welcome to Deloitte

If we have selected the wrong experience for you, please change it above.

Perspective:
Perspective
01 Dec 2023

What’s next for Health Care Professional (HCP) Engagement?

What’s next for HCP Engagement?
Download PDF (4MB) View PDF

HCP ‘engagement’ describes the model of how biopharma companies engage with their customers and typically covers a broad range of synchronised front line and back-office activities.
 

What does it mean for a biopharma company to truly excel at HCP engagement?


This primer explores the topic in the context of a biopharma company’s operating model and capabilities needed for best-in-class HCP engagement that is adaptive for the future.

Skip to description

Get in touch

Dr. Philipp Mayrl

Dr. Philipp Mayrl

Partner
+41 58 279 7370

Did you find this useful?

Yes
No

Thanks for your feedback

Your feedback is important to us

To tell us what you think, please update your settings to accept analytics and performance cookies.

Need help updating cookies?

Our thinking

Commercial Operations in Life Sciences

Digital transformation of commercial operations has transitioned from a “nice-to-have” enabler to a “must-have” capability, making it critical for Life Science companies to evaluate how digital tools will deliver customer centricity and service innovation (collectively termed Commercial Excellence) across the commercial operations value chain.
Perspective

Accelerating to the Future of Customer Engagement

Accelerating to the Future of Customer Engagement
Perspective

Digital health

Digital health is a broad category of technologies targeting various steps across the patient journey. They typically address (1) disease prevention, (2) improvement of treatment outcomes, or (3) support of healthcare providers in delivering better medical services
Service

Accelerating commercialisation of RNA Therapeutics and Vaccines

Deloitte has successfully supported Biotech companies in scaling up fast and overcoming operational challenges in the mRNA field. In the successful deployment of mRNA vaccines against COVID-19 Deloitte's team of experts acted as catalysts to ensure high speed in the supply chain operations. Learn how Deloitte can help your company thrive in the mRNA value chain.
Perspective
Explore our thinking

Let's connect

Deloitte AG is a shareholder in Deloitte EMEA BV (EMEA), which is a member firm of Deloitte Touche Tohmatsu Limited (DTTL). Deloitte EMEA and DTTL do not provide services to clients. Services may be provided by the EMEA shareholders or their affiliates, which are separate and independent legal entities. Please see www.deloitte.com/ch/about to learn more about our global network of member firms.

This communication contains general information only, and none of Deloitte EMEA (EMEA), its shareholders and affiliates is, by means of this communication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser.

No representations, warranties, or undertakings (express or implied) are given as to the accuracy or completeness of the information in this communication, and none of EMEA, the EMEA shareholders, their respective affiliates, employees or agents shall be liable or responsible for any loss or damage whatsoever arising directly or indirectly in connection with any person relying on this communication. EMEA, the EMEA shareholders and their respective affiliates are legally separate and independent entities.

Deloitte AG is an audit firm recognised and supervised by the Federal Audit Oversight Authority (FAOA) and the Swiss Financial Market Supervisory Authority (FINMA).

© 2026  For information, contact Deloitte AG.